Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1‐year multicentre study
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Aims To evaluate the long‐term effectiveness and safety of repaglinide, a novel prandial glucose regulator, in comparison with glipizide in the treatment of patients with Type 2 diabetes. Methods Diet or tablet‐treated patients with Type 2 diabetes (n = 256; age 40–75 years, body mass index (BMI) 20–35 kg/m 2, HbA 1c 4.2–12.8%), without signs of severe microvascular or macrovascular complications, were included in this double‐blind, multicentre, parallel‐group comparative trial. Patients were randomized at a 2:1 ratio to repaglinide, 1–4 mg at mealtimes, or glipizide, 5–15 mg daily. Results Changes in fasting blood glucose (FBG) and HbA 1c during the 12 months of treatment showed a significant difference in favour of repaglinide. In oral hypoglycaemic agents (OHA)‐naive patients, HbA 1c decreased in the repaglinide and glipizide groups by 1.5% and 0.3%, respectively (P < 0.05 between groups). Fasting blood glucose decreased in the repaglinide group by 2.4 mmol/l and increased in the glipizide group by 1.0 mmol/l (P < 0.05 between groups). In the study population as a whole, repaglinide was able to maintain glycaemic control (HbA 1c level) during the 1‐year study period, whereas control deteriorated significantly with glipizide. Change in HbA 1c from baseline was significantly better with repaglinide than with glipizide after 12 months (P < 0.05). In addition, FBG deteriorated significantly in the glipizide group compared with the repaglinide group (P < 0.05). No patients in either group experienced a major hypoglycaemic event; the number of patients experiencing minor hypoglycaemia was similar in the repaglinide and glipizide groups (15% and 19%, respectively). Conclusions Repaglinide, given as a prandial glucose regulator, is shown to be an effective and safe treatment of patients with Type 2 diabetes, and is better than glipizide in controlling HbA 1c and FBG levels, overall, and in OHA‐naive patients. Diabet. Med. 18, 395–401 (2001)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
(1999) · The Lancet · doi:10.1016/s0140-6736(98)12131-1 · Cited by 1,313
A desktop guide to Type 2 diabetes mellitus
European Diabetes Policy Group, 1. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00166.x · Cited by 670
Groop, L. C. (1992) · Diabetes Care · doi:10.2337/diacare.15.6.737 · Cited by 408
Fuhlendorff, J., Rorsman, P., Kofod, H., Brand, C. L., Rolin, B., MacKay, P., Shymko, R., & Carr, R. D. (1998) · Diabetes · doi:10.2337/diabetes.47.3.345 · Cited by 310
Damsbo, P., Clauson, P., Marbury, T. C., & Windfeld, K. (1999) · Diabetes Care · doi:10.2337/diacare.22.5.789 · Cited by 118
Cited by
Qaseem, A., Humphrey, L. L., Sweet, D. E., Starkey, M., Shekelle, P., & for the Clinical Guidelines Committee of the American College of Physicians* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-3-201202070-00011 · Cited by 400
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.86 · Cited by 398
Clinical Significance, Pathogenesis, and Management of Postprandial Hyperglycemia
Gerich, J. E. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.11.1306 · Cited by 321
The Role of Sulphonylureas in the Management of Type 2 Diabetes Mellitus
Rendell, M. (2004) · Drugs · doi:10.2165/00003495-200464120-00006 · Cited by 308
A review of the efficacy and safety of oral antidiabetic drugs
Stein, S. A., Lamos, E. M., & Davis, S. N. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.752813 · Cited by 305
Metadata
- Authors
- Madsbad, S., Kilhovd, B., Lager, I., Mustajoki, P., Dejgaard, A., & for the Scandinavian Repaglinide Group
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 2001-05
- Volume
- 18
- Issue
- 5
- Pages
- 395-401
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W2132308332
- Cited by
- 79
- References
- 6
- FWCI
- 4.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1‐year multicentre study. https://app.cochat.ai/papers/10.1046/j.1464-5491.2001.00490.x
- The paper
- Madsbad, S., Kilhovd, B., Lager, I., Mustajoki, P., Dejgaard, A., & for the Scandinavian Repaglinide Group. (2001). Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1‐year multicentre study. Diabetic Medicine. https://doi.org/10.1046/j.1464-5491.2001.00490.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.